Chelerytrine, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
Average 91 stars, based on 1 article reviews
Price from $9.99 to $1999.99
1) Product Images from "Opposed Actions of PKA Isozymes (RI and RII) and PKC Isoforms (cPKCβI and nPKCε) in Neuromuscular Developmental Synapse Elimination"
Article Title: Opposed Actions of PKA Isozymes (RI and RII) and PKC Isoforms (cPKCβI and nPKCε) in Neuromuscular Developmental Synapse Elimination
Figure Legend Snippet: PKC activity modulation in axonal loss. ( A ) shows the percentage of singly-, doubly-, and triply- (or more) innervated NMJs in the control mice (PBS) and after four applications of one of the following substances: the PKC paninhibitors Chelerytrine (CHE) and CaC, and the PKC panstimulators (BRY, at 1 and 10 nM) and PMA. CHE and CaC action results in the persistence of many polyinnervated synapses. Accordingly, both PKC stimulators PMA and BRY increase the number of monoinnervated junctions and clearly decrease the percentage of doubly-innervated junctions in the case of BRY. ( B ) shows the percentage of singly-, doubly-, and triply (or more) innervated NMJs after exposure to the cPKCβI and nPKCε isoform selective inhibitors βIV 5–3 and εV 1–2 , and the cPKCβI and nPKCε selective activators dPPA and FR 236,924 respectively. The selective inhibitors similarly increase the doubly- and triply-innervated synapses with the corresponding reduction in the monoinnervated junctions. The activators considerably accelerate nerve terminal elimination. Data were presented as percentages of NMJ ± SD (for each treatment and PBS control: n pups = 6–9; n = 11–18 LALs; n NMJ: PBS: 2538; Bry 1 nM: 1232 Bry 10 nM:1384; PMA:1247; CaC: 1573; Che:1499; βIV 5–3 : 1275; dPPA: 1121; εV 1–2 :1663 and FR 236924: 1367). Fisher’s test: * p
Techniques Used: Activity Assay, Mouse Assay